Olr748 inhibitors are a class of chemical compounds specifically designed to interact with the olfactory receptor 748 (Olr748). These compounds function by binding to the receptor, thereby altering its normal signaling pathway. Olr748 is part of the extensive family of G-protein coupled receptors (GPCRs), which play crucial roles in transducing extracellular signals into intracellular responses. Inhibitors targeting Olr748 are typically small molecules that exhibit high affinity and specificity for the receptor, allowing precise modulation of its activity. The design and synthesis of Olr748 inhibitors involve sophisticated techniques in medicinal chemistry, including structure-activity relationship (SAR) studies, which help in understanding the molecular features critical for binding and activity.
From a structural perspective, Olr748 inhibitors often possess a core framework that enables optimal interaction with the receptor's binding site. This core is usually surrounded by functional groups that enhance the inhibitor's binding affinity and specificity. Advanced computational modeling and crystallography are employed to visualize the receptor's three-dimensional structure, guiding the rational design of these inhibitors. Additionally, synthetic routes to these compounds are carefully optimized to yield high-purity products, facilitating their use in various research applications. The development of Olr748 inhibitors also involves extensive in vitro and in vivo studies to evaluate their efficacy in modulating olfactory signaling. These studies contribute to a deeper understanding of olfactory receptor functions and their broader physiological roles, providing valuable insights into the fundamental mechanisms of sensory perception.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING | 
|---|---|---|---|---|---|---|
| Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
| EGFR and HER2 inhibitor, potentially affecting proteins in associated signaling pathways. | ||||||
| Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
| CDK4/6 inhibitor, potentially disrupting cell cycle regulation proteins. | ||||||
| Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
| JAK1 and JAK2 inhibitor, potentially affecting proteins in JAK-STAT signaling pathways. | ||||||
| Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
| Multi-kinase inhibitor, potentially disrupting proteins in angiogenesis and growth factor signaling pathways. | ||||||
| Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
| HDAC inhibitor, potentially affecting gene expression and associated protein pathways. | ||||||
| Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
| BCR-ABL and Src kinase inhibitor, potentially affecting proteins in leukemia signaling pathways. | ||||||
| Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
| EGFR inhibitor, potentially affecting proteins in the EGFR signaling pathway. | ||||||
| Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
| EGFR inhibitor, potentially disrupting proteins in the EGFR signaling pathway. | ||||||
| Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
| BCR-ABL, c-Kit, and PDGFR inhibitor, potentially affecting proteins in associated signaling pathways. | ||||||
| Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
| BCR-ABL inhibitor, potentially disrupting proteins in leukemia signaling pathways. | ||||||